INTRODUCTION
Osteoporosis, with an estimated prevalent population of over 127 million in the seven major markets and valued at around $7 billion in 2002,
presents a commercially attractive target for development.
SCOPE OF THE REPORT
- Survey of 160 treating physicians in the seven major markets, with in-depth interviews with osteoporosis opinion leaders
- Detailed treatment trees show the proportion of patients screened, presented, diagnosed and receiving treatment, by disease severity and country
- Review of the use of combination therapy in key patient and physician populations, and of physician perception of R&D trends & potential
of novel drugs
- Investigation of therapeutic and diagnostic unmet needs, highlighting areas where pharma investment is vital to drive patient identification
REPORT HIGHLIGHTS
Datamonitor's research has identified strong variances in class and brand prescribing preferences among physicians, according to both disease
severity and geography. Combination therapy is prescribed in the US, Japan, the UK, France and Spain, though not in Italy and Germany.
Just 10% of
the prevalent population in the seven major markets are diagnosed; just over half of those are drug treated. Market growth depends on driving patient
identification and diagnosis: potential barriers to growth include low disease awareness and limited access to and utilization of diagnostic tools.
Three
developments have the potential to radically change treatment and expand the market: SERMs in additional indications; PTH/anabolic drugs in fracture
patients and novel bisphosphonates in flexible dosing and delivery formulations.
KEY REASONS TO BUY THIS REPORT
- Understand physician prescribing behavior by specialty
- Identify differential treatment and unmet needs in key patient populations identified by sex and disease severity
- Validate new product forecasting based on diagnosis and treatment rates, and potential uptake for a new product based on physicians' perceptions
View Cart
